ESPE Abstracts

Introduction: GLP-1 analogues are promising agents for the pharmacotherapy of obesity due to their combined effect on metabolic signalization and eating behavior. The GLP-1 analog liraglutide is registered in Europe for therapy of obese adolescents aged 12-17 years since 2021. According to clinical studies, liraglutide administration leads to a mean weight loss 4.6%. We summarize early real-life experience with this novel therapy.<strong...